Wednesdays News at a glance:
Barking mad – Freak Show…Happy to Oblige – The Man Behind The Finding That Vaping is 95% Safer Than Smoking – Public Health Malpractice? – A threat for European vapers – Why e-cigarettes have an image problem – States Planning To Hit Vapers With E-Cigarette Taxes – Vapor Products and Tax Policy – Taxes Discourage Smokers from Switching to E-Cigarettes – Clinical Trials and Errors Blur Consumer Tobacco Preferences – Nicotine Science and Policy Daily Digest – Wednesday, 23 March 2016
Dog and cat owners who use e-cigarettes are being warned to keep them as far away as possible from their pets….Er, why?
The warning comes after the Pet Poison Hotline announced there has been a 400-percent jump in the last two years, in pets being poisoned by e-cigarettes.
Maybe nobody showed those pets how to use an e-cigarette?
The Vapor Bar
And the side show continues, does it not? The race to create the most asinine labels, treading blatantly close to the trademark border that separates a known product from e-liquid, and the deliberate cloud blowing in personal public places that attracts and offends others. Trademarks… well they’ll send those cease and desist letters and file lawsuits against them, so they’ll drown in their own cesspool…..
That Vaping is 95% Safer Than Smoking – The Drip Club
David Nutt has an interesting history, and has caused quite a bit of controversy in his career by remaining scientific in the face of poorly thought-out drug policy. Nutt is a British psychiatrist and neuropsychopharmacologist who has a very impressive list of academic accomplishments…
Nursing Journal Article Recommends Scolding Smokers Who Quit Using E-Cigarettes – The Rest of the Story
In a review article published online ahead of print Monday in theJournal of the American Association of Nurse Practitioners, a University of Pennsylvania Nursing School professor makes a number of clinical recommendations regarding communications that nurses should have with patients about tobacco and nicotine use. One of those recommendations is that practitioners should not commend smokers who have successfully quit smoking by switching completely to electronic cigarettes.
Jérôme Harlay – PGVG
The German Federal Office for Chemicals (GFOC), in October 2015 submitted a proposal to the European Chemicals Agency (ECHA) for a new toxicological classification of propylene glycol (PG). The “implications of such a classification might be devastating for vapers”, according to the chemist Mirosław Dworniczak….
— Juhani Orelma (@j_orelma) March 23, 2016
Jacob Hasselbalch – OUPBlog
E-cigarettes have an image problem. I mean this in two different ways. They are still seen as controversial products, often featuring in dramatic stories about battery explosions or toxic substances. Most of these stories play on public fears, exaggerate their claims, and are unhelpful for fostering a constructive public debate.
With E-Cigarette Taxes – Guy Bentley
More than 20 states considered imposing taxes on vapor products in 2015 and as of Jan 1., four have already implemented them.
A Tax Foundation report released Tuesday maps the entire country and reveals which states have been most eager to hit vapers with excise taxes.
Scott Drenkard – Tax Foundation Blog
One of the main challenges for policymakers is determining how these emerging products should be treated with respect to tax policy. Excise taxes as a whole make up 3 percent of the federal budget, and tobacco taxes specifically comprise an average of 2 percent of state budgets
Poorly planned tax measures may prevent smokers in the USA from dropping the habit in favor of less harmful e-cigarettes.
On March 22nd the US think-tank the Tax Foundation released a new report on the taxation of electronic cigarettes in the USA, calling for state governments to ensure that they do not tax the new vaporizer technologies in the same way that they would tax traditional tobacco products…
Brad Rodu – Tobacco Truth
Doctors, myself included (here, here and here), value clinical trials, for good reason: They are powerful tools using sophisticated scientific methods to precisely determine the effectiveness of treatments for specific diseases. But clinical trials are ill-suited to the measurement of consumers’ preferences for products in the marketplace. The appropriate tool for that is post-market surveillance.